Mind Medicine (MNMD) said Tuesday that it dosed the first patient in the phase 3 study evaluating MM120 orally disintegrating tablet or ODT, for the treatment of major depressive disorder.
The study will evaluate 100 microgram doses of the drug candidate for efficacy and safety compared with placebo in about 140 participants in the US, according to the company.
The company said the trial will consist of a 12-week randomized, double blind, placebo-controlled study followed by a 40-week open-label period. Top-line data from the first part is expected in the second half of 2026.
MM120 ODT is a pharmaceutically optimized form of lysergide D-tartrate or LSD, Mind Medicine added.
Shares of the company were up 3.2% in recent trading.
Price: 5.78, Change: +0.23, Percent Change: +4.14
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.